NFE And Ebrasil To Sell Porto De Sergipe Power Plant For Apprx. $1.29 Bln Cash

New Fortress Energy Inc. (NFE) on Wednesday said it has, along with its partner Ebrasil Energia Ltda. agreed to sell Porto de Sergipe Power Plant to Brazilian power company Eneva S.A. for R$6.1 billion or $1.29 billion in cash.

As part of the deal, Eneva has agreed to acquire all shares of Centrais Elétricas de Sergipe Participações S.A. (CELSEPAR), who owns the 1,593 MW Sergipe Power Plant, and Centrais Elétricas Barra dos Coqueiros S.A., which owns 1.7 GW of expansion rights adjacent to the Sergipe Power Plant, for a total implied enterprise value of about R$10.2 billion, including debt.

"NFE will continue to operate the Golar Nanook, a Floating Storage and Regasification Unit that remains chartered to CELSE for the next 20 years," said Wes Edens, Chairman and CEO of New Fortress Energy.

The transaction, which is projected to bring in about $550 million proceeds to New Fortress Energy, is expected to close in the second half of 2022.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Longmont Colorado -based Royal Crest Dairy is recalling 2% Chocolate Milk citing the potential to be contaminated with undeclared egg, a known allergen, the U.S. Food and Drug Administration said. The recall involves Farmer's 2% Reduced Fat Chocolate Milk Pints with the code date of AUG-22. ANI Pharmaceuticals, Inc. (ANIP) Monday announced a wider loss for the second quarter, despite a 52 percent surge in revenues. For the full year 2022, the company reiterated the adjusted earnings per share range, revenue guidance and raised Cortrophin revenue outlook. The company reported a quarterly... Shares of BioNTech SE were losing around 4 percent in the morning trading in Germany and around 5 percent in the pre-market activity on Nasdaq after the German Covid-19 vaccine maker reported sharp drop in profit and revenues for the second quarter. However, the company recorded strong growth in first-half results. Further, the company maintained BioNTech COVID-19 vaccine revenue guidance
Follow RTT